Key Drivers
- Liquidity Pressure
- Heavy Cash Burn
- Rich Valuation
AIAI Summary
MESO is transitioning from a purely speculative biotech into a real commercial story with Ryoncil traction and high gross margins, but the key investment takeaway is that it still must prove revenue can outpace heavy burn and reduce reliance on external financing before the valuation can rerate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Pressure
- •Heavy Cash Burn
- •Rich Valuation
MESO has adequate liquidity and strong gross margins, but rising leverage, persistent losses, negative cash flow, and a demanding valuation make it financially weak overall.
Price Behavior
Key Price Behavior Insights:
- •Low-$13 Support
- •Mid-Teens Ceiling
- •Volatile Rebound
MESO has been range-bound over the last month, rebounding from the low $13s but still struggling to reclaim the $14.50-$15.00 area after repeated failures near $15.50.
Sharp drop from $15.55 to $13.19 showed elevated volatility and weak follow-through
Sentiment & News
Key News Insights:
- •Capital boost
- •FDA filing
- •Regulatory progress
Mesoblast strengthened its balance sheet with a US$50 million drawdown while advancing rexlemestrocel-L's FDA filing, improving near-term financing and regulatory visibility.
This news is modestly positive for the instrument as it reduces financing pressure while keeping a key therapeutic asset on a clearer approval path
Similar Companies in Healthcare
Other companies in the same sector with AI ratings